“…Three novel nonselective MT 1 /MT 2 agonists, TIK-301 (Zemlan et al, 2005), ramelteon (Mini et al, 2007), and tasimelteon (Rajaratnam et al, 2009), have been tested in humans for the treatment of insomnia; all three significantly reduced the latency to sleep, but were less potent in potentiating the long-term enhancement of total sleep time and without selectivity toward NREMS or REMS. The nonselective antidepressant MT 1 /MT 2 agonist agomelatine improves sleep after 6 weeks of treatment (Quera Salva et al, 2007), but its mechanisms of action remain to be elucidated, as it also binds to serotonergic 5-HT 2B and 5-HT 2C receptors, already known to be involved in sleep (Den Boer et al, 2006).…”